{"success":true,"data":{"pressRelease":{"id":"163398","rtpr_id":"nBw311fJRa-20261007","ticker":"ALOPM","exchange":"Euronext Paris","all_tickers":["ALOPM"],"title":"OPM Achieved Several Major Scientific and Regulatory Milestones as Part of the LARKIN Program, Supported With Funding By The Michael J. Fox Foundation for Parkinson's Research (MJFF)","author":"Business Wire","published_at":"2026-10-07T16:00:00.389Z","article_body":"OPM Achieved Several Major Scientific and Regulatory Milestones as Part of the\nLARKIN Program, Supported With Funding By The Michael J. Fox Foundation for\nParkinson's Research (MJFF)\n\n\n * MJFF confirms its support to the program with the payment of an additional\nfunding tranche\n\n * Successful micronization of the active pharmaceutical ingredient and\nmanufacturing of the first technical batches of OPM-201 tablets\n\n * European Medicines Agency (EMA) support for OPM’s proposed long-term\ntoxicology strategy\n\n * Preparation of the next regulatory and clinical development steps for OPM-201,\nwith the objective of initiating a Phase 1b trial in patients with\nParkinson’s disease in 2027\n\nRegulatory News:\n\nOncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol:\nALOPM), a biopharmaceutical company specializing in precision medicine, today\nannounced several strategic advances in the development of OPM-201, its LRRK2\nkinase inhibitor for the treatment of Parkinson’s disease.\n\nThese advances come six months after the launch of the LARKIN program,\nsupported by a grant from The Michael J. Fox Foundation for Parkinson’s\nResearch (MJFF) through its Therapeutic Pipeline Program (TPP) which supports\npromising Parkinson’s therapies from preclinical research through clinical\ntesting. This funding notably supports the manufacturing of the drug product\nrequired for the next stages of clinical development, as well as the long-term\ntoxicology program for OPM-201.\n\nSince the launch of the LARKIN program, OPM has achieved several key\nmilestones in pharmaceutical manufacturing, non-clinical development and\nregulatory preparation, in line with the objectives of the LARKIN program.\nMJFF continues to support the program by liberating an additional funding\ntranche.\n\nKey manufacturing milestones achieved in preparation for Phase 1b\n\nPharmaceutical development activities conducted with the Contract Development\nand Manufacturing Organization (CDMO) selected by OPM have progressed\nsignificantly.\n\nMicronization of the OPM-201 active pharmaceutical ingredient (API) has been\ncompleted, and feasibility batches followed by technical batches of the drug\nproduct, comprising active and placebo tablets, have been successfully\nmanufactured and met the quality criteria assessed during production. The CDMO\nquality audit has also been completed.\n\nThese advances now enable OPM to proceed with the transfer of analytical\nmethods and prepare for the GMP manufacturing of tablets to be used in the\nfuture Phase 1b clinical trial.\n\nOPM advances the preclinical development required for future clinical stages\n\nA key regulatory milestone has also been achieved in preparation for the\nlong-term development of OPM-201. Following a scientific advice request\nsubmitted by OPM in April 2026, the European Medicines Agency’s Committee\nfor Medicinal Products for Human Use (CHMP) endorsed on July 23, 2026, the\nregulatory long-term toxicology study plan proposed by OPM to support the\nclinical development of OPM-201.\n\nA contract research organization has been selected to conduct this GLP study.\nThe main phase of the study is expected to begin in the first half of 2027.\n\nIn parallel, a comparative metabolism study of OPM-201 in human hepatocytes\nand hepatocytes from various preclinical species has been completed. The\nresults provide additional data supporting the toxicology strategy and the\npreparation of upcoming regulatory interactions.\n\nActive preparation for the next clinical stage\n\nIn parallel, OPM continues to prepare for the Phase 1b trial of OPM-201 in\npatients with Parkinson’s disease. In-depth pharmacokinetic/pharmacodynamic\nmodeling is underway based on data generated in the Phase 1 study in healthy\nvolunteers. This work is intended to optimize dose selection and the dosing\nregimen for the next clinical trial.\n\nThis work will notably support upcoming interactions with the U.S. Food and\nDrug Administration (FDA). OPM is currently preparing a pre-IND meeting\nrequest, with the objective of discussing the dose strategy and dosing regimen\nfor the Phase 1b trial. IND submission is currently planned for early 2027.\n\nPhilippe Genne, co-founder, President and Chief Executive Officer of OPM,\nsaid: “Six months after the launch of the LARKIN program with the support of\nThe Michael J. Fox Foundation, we have achieved several key milestones in the\ndevelopment of OPM-201. Our objective is now to maintain this momentum as we\nprepare for the evaluation of OPM-201 in patients with Parkinson’s disease\nin 2027. The LARKIN program remains on budget, and on August 27, 2026, OPM\nreceived a second payment from The Michael J. Fox Foundation following the\nachievement of the milestones defined under the program. We thank the\nFoundation for its continued confidence and for its commitment to patients\nliving with Parkinson’s disease.”\n\nDr. Jan Hoflack, co-founder and Chief Scientific Officer of OPM, added: “The\nprogress achieved over the past six months strengthens our confidence in the\ndevelopment path of OPM-201. The manufacturing of the first technical batches,\ntogether with the CHMP’s scientific advice on our long-term toxicology\nstrategy, represent important milestones in supporting the continued\ndevelopment of the candidate. In parallel, our teams are actively preparing\nfor the next clinical phase, which will enable us to further characterize\nOPM-201 and evaluate it in patients with Parkinson’s disease. All this work\nis aimed at building a robust development program designed to fully assess the\npotential of OPM-201 as a selective LRRK2 inhibitor.”\n\nAbout OPM-201\n\nOPM-201 is a macrocyclic inhibitor of the LRRK2 kinase derived from Oncodesign\nPrecision Medicine’s Nanocyclix(®) platform. LRRK2 is an important\ntherapeutic target in Parkinson’s disease, particularly in certain genetic\nforms of the disease. Initiated in 2011 and developed through several\npartnerships with companies specializing in neurological diseases, the program\nwas advanced internally by Oncodesign from 2017 before entering into a\ncollaboration with Servier in 2019. This collaboration led to the\nidentification of a drug candidate in 2021, followed by preclinical and CMC\ndevelopment activities. A first Phase 1 clinical trial in healthy volunteers\nsubsequently demonstrated a favorable tolerability profile, with no serious\nadverse events observed, as well as LRRK2 target engagement in volunteers who\nreceived the highest dose, supporting the potential of OPM-201 as a\n“best-in-class” candidate. OPM regained full rights to the program from\nServier in December 2024 and is now responsible for its development. In\nFebruary 2026, OPM-201 was also selected by The Michael J. Fox Foundation to\nreceive funding through its Therapeutic Pipeline Program.\n\nAbout Parkinson’s disease\n\nParkinson’s disease is a progressive neurodegenerative disorder affecting 1%\nof the population over the age of 60. The disease, which affected nearly 12\nmillion people worldwide in 2021, is characterized by the progressive loss of\ndopaminergic neurons. The LRRK2 gene is a major therapeutic target in\nParkinson’s disease. Activating mutations in the LRRK2 gene are associated\nwith hereditary forms of Parkinson’s disease. Along with alpha-synuclein,\nLRRK2 is one of the few targets considered to have the potential to modify the\ncourse of the disease. Current treatments are largely symptomatic and aim to\nincrease dopamine levels in the vicinity of the remaining dopaminergic\nneurons.\n\nAbout Oncodesign Precision Medicine (OPM)\n\nOncodesign Precision Medicine (OPM), founded in 2022, is a biopharmaceutical\ncompany specializing in precision medicine, dedicated to discovering\ntreatments for resistant and metastatic cancers.\n\nOPM currently has two kinase inhibitors in clinical phase:\n\n\n 1. OPM-101, intended for the treatment of chronic immuno-inflammatory digestive\ndiseases and immuno-oncology, has demonstrated a significant therapeutic\nmargin and absence of toxicity in its phase I healthy volunteers with the\nprotocol for the Phase 1b/2a oncology trial submitted at the end of March 2025\nand accepted in September 2025.\n\n 2. OPM-201, initially licensed to Servier and intended for the treatment of\nParkinson's disease, completed its phase I trial in healthy volunteers at the\nend of 2024, and was reintegrated into OPM's portfolio. In February 2026, OPM\nreceived funding from the Michael J. Fox Foundation for this program to\nprepare for the launch of a Phase 1b trial in 2027 involving people with\nearly-stage Parkinson’s disease, with a focus on those carrying an LRRK2\ngene mutation\n\nBoth molecules come from the Nanocyclix(®) technology platform, which enables\nthe design and selection of small, highly effective and selective macrocyclic\nkinase inhibitors. We now have 12,000 molecules in our library and will be\nusing AI to accelerate the discovery of drug candidates while reducing the\ncost of this phase.\n\nOPM's other two technology platforms are:\n\n\n * OncoSNIPER, for the selection of therapeutic targets using artificial\nintelligence,\n\n * PROMETHE(®) for the design and selection of radiolabeled biological molecules\nfor systemic radiotherapy.\n\nOPM, co-founded by Philippe Genne, Jan Hoflack and Karine Lignel, is based in\nDijon, at the heart of the university and hospital cluster, and employs 14\npeople.\n\nMore info at: oncodesign.com\n\nForward-looking statements\n\nThis document contains forward-looking statements and estimates with respect\nto the financial condition, results of operations, strategy, plans and future\nperformance of the Company and the market in which it operates. Some of these\nstatements, forecasts and estimates can be identified by the use of words such\nas, without limitation, \"believes\", \"anticipates\", \"expects\", \"projects\",\n\"plans\", \"seeks\", \"estimates\", \"may\", \"will\" and \"continue\" and other similar\nexpressions. They include all matters that are not historical facts. Such\nstatements, forecasts and estimates are based on various assumptions and\nassessments of known and unknown risks, uncertainties and other factors, which\nwere believed to be reasonable when they were made but which may not prove to\nbe correct. Actual events are difficult to predict and may depend on factors\nbeyond the Company's control. Consequently, the actual results, financial\nconditions, performance or achievements of the Company, or industry results,\nmay differ materially from future results, performance or achievements as\nexpressed or implied by such statements, forecasts and estimates. Given these\nuncertainties, no representation is made as to the accuracy or fairness of\nsuch forward-looking statements, forecasts and estimates. Furthermore, the\nforward-looking statements, forecasts and estimates speak only as of the date\nof publication of this document. The Company disclaims any obligation to\nupdate these forward-looking statements, forecasts or estimates to reflect any\nchange in the Company's expectations with regard thereto, or any change in\nevents, conditions or circumstances on which these statements, forecasts or\nestimates are based, except as required by French law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261007877096/en/\n(https://www.businesswire.com/news/home/20261007877096/en/)\n\nOPM \n\nKarine Lignel\n\nDeputy General Manager\n\nTel: +33 (0)310 451 820\n\ninvestisseurs@oncodesign.com (mailto:investisseurs@oncodesign.com)\n\nNewCap \n\nInvestor Relations\n\nMathilde Bohin / Alban Dufumier\n\nTel: +33 (0)1 44 71 94 95\n\noncodesign@newcap.eu (mailto:oncodesign@newcap.eu)\n\nNewCap \n\nMedia Relations\n\nArthur Rouillé\n\nTel: +33 (0)1 44 71 00 15\n\noncodesign@newcap.eu (mailto:oncodesign@newcap.eu)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw311fJRa-20261007","title":"OPM Achieved Several Major Scientific and Regulatory Milestones as Part of the LARKIN Program, Supported With Funding By The Michael J. Fox Foundation for Parkinson's Research (MJFF)","author":"Business Wire","ticker":"ALOPM","created":"2026-10-07T16:00:00.389Z","tickers":["ALOPM"],"exchange":"Euronext Paris","article_body":"OPM Achieved Several Major Scientific and Regulatory Milestones as Part of the\nLARKIN Program, Supported With Funding By The Michael J. Fox Foundation for\nParkinson's Research (MJFF)\n\n\n * MJFF confirms its support to the program with the payment of an additional\nfunding tranche\n\n * Successful micronization of the active pharmaceutical ingredient and\nmanufacturing of the first technical batches of OPM-201 tablets\n\n * European Medicines Agency (EMA) support for OPM’s proposed long-term\ntoxicology strategy\n\n * Preparation of the next regulatory and clinical development steps for OPM-201,\nwith the objective of initiating a Phase 1b trial in patients with\nParkinson’s disease in 2027\n\nRegulatory News:\n\nOncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol:\nALOPM), a biopharmaceutical company specializing in precision medicine, today\nannounced several strategic advances in the development of OPM-201, its LRRK2\nkinase inhibitor for the treatment of Parkinson’s disease.\n\nThese advances come six months after the launch of the LARKIN program,\nsupported by a grant from The Michael J. Fox Foundation for Parkinson’s\nResearch (MJFF) through its Therapeutic Pipeline Program (TPP) which supports\npromising Parkinson’s therapies from preclinical research through clinical\ntesting. This funding notably supports the manufacturing of the drug product\nrequired for the next stages of clinical development, as well as the long-term\ntoxicology program for OPM-201.\n\nSince the launch of the LARKIN program, OPM has achieved several key\nmilestones in pharmaceutical manufacturing, non-clinical development and\nregulatory preparation, in line with the objectives of the LARKIN program.\nMJFF continues to support the program by liberating an additional funding\ntranche.\n\nKey manufacturing milestones achieved in preparation for Phase 1b\n\nPharmaceutical development activities conducted with the Contract Development\nand Manufacturing Organization (CDMO) selected by OPM have progressed\nsignificantly.\n\nMicronization of the OPM-201 active pharmaceutical ingredient (API) has been\ncompleted, and feasibility batches followed by technical batches of the drug\nproduct, comprising active and placebo tablets, have been successfully\nmanufactured and met the quality criteria assessed during production. The CDMO\nquality audit has also been completed.\n\nThese advances now enable OPM to proceed with the transfer of analytical\nmethods and prepare for the GMP manufacturing of tablets to be used in the\nfuture Phase 1b clinical trial.\n\nOPM advances the preclinical development required for future clinical stages\n\nA key regulatory milestone has also been achieved in preparation for the\nlong-term development of OPM-201. Following a scientific advice request\nsubmitted by OPM in April 2026, the European Medicines Agency’s Committee\nfor Medicinal Products for Human Use (CHMP) endorsed on July 23, 2026, the\nregulatory long-term toxicology study plan proposed by OPM to support the\nclinical development of OPM-201.\n\nA contract research organization has been selected to conduct this GLP study.\nThe main phase of the study is expected to begin in the first half of 2027.\n\nIn parallel, a comparative metabolism study of OPM-201 in human hepatocytes\nand hepatocytes from various preclinical species has been completed. The\nresults provide additional data supporting the toxicology strategy and the\npreparation of upcoming regulatory interactions.\n\nActive preparation for the next clinical stage\n\nIn parallel, OPM continues to prepare for the Phase 1b trial of OPM-201 in\npatients with Parkinson’s disease. In-depth pharmacokinetic/pharmacodynamic\nmodeling is underway based on data generated in the Phase 1 study in healthy\nvolunteers. This work is intended to optimize dose selection and the dosing\nregimen for the next clinical trial.\n\nThis work will notably support upcoming interactions with the U.S. Food and\nDrug Administration (FDA). OPM is currently preparing a pre-IND meeting\nrequest, with the objective of discussing the dose strategy and dosing regimen\nfor the Phase 1b trial. IND submission is currently planned for early 2027.\n\nPhilippe Genne, co-founder, President and Chief Executive Officer of OPM,\nsaid: “Six months after the launch of the LARKIN program with the support of\nThe Michael J. Fox Foundation, we have achieved several key milestones in the\ndevelopment of OPM-201. Our objective is now to maintain this momentum as we\nprepare for the evaluation of OPM-201 in patients with Parkinson’s disease\nin 2027. The LARKIN program remains on budget, and on August 27, 2026, OPM\nreceived a second payment from The Michael J. Fox Foundation following the\nachievement of the milestones defined under the program. We thank the\nFoundation for its continued confidence and for its commitment to patients\nliving with Parkinson’s disease.”\n\nDr. Jan Hoflack, co-founder and Chief Scientific Officer of OPM, added: “The\nprogress achieved over the past six months strengthens our confidence in the\ndevelopment path of OPM-201. The manufacturing of the first technical batches,\ntogether with the CHMP’s scientific advice on our long-term toxicology\nstrategy, represent important milestones in supporting the continued\ndevelopment of the candidate. In parallel, our teams are actively preparing\nfor the next clinical phase, which will enable us to further characterize\nOPM-201 and evaluate it in patients with Parkinson’s disease. All this work\nis aimed at building a robust development program designed to fully assess the\npotential of OPM-201 as a selective LRRK2 inhibitor.”\n\nAbout OPM-201\n\nOPM-201 is a macrocyclic inhibitor of the LRRK2 kinase derived from Oncodesign\nPrecision Medicine’s Nanocyclix(®) platform. LRRK2 is an important\ntherapeutic target in Parkinson’s disease, particularly in certain genetic\nforms of the disease. Initiated in 2011 and developed through several\npartnerships with companies specializing in neurological diseases, the program\nwas advanced internally by Oncodesign from 2017 before entering into a\ncollaboration with Servier in 2019. This collaboration led to the\nidentification of a drug candidate in 2021, followed by preclinical and CMC\ndevelopment activities. A first Phase 1 clinical trial in healthy volunteers\nsubsequently demonstrated a favorable tolerability profile, with no serious\nadverse events observed, as well as LRRK2 target engagement in volunteers who\nreceived the highest dose, supporting the potential of OPM-201 as a\n“best-in-class” candidate. OPM regained full rights to the program from\nServier in December 2024 and is now responsible for its development. In\nFebruary 2026, OPM-201 was also selected by The Michael J. Fox Foundation to\nreceive funding through its Therapeutic Pipeline Program.\n\nAbout Parkinson’s disease\n\nParkinson’s disease is a progressive neurodegenerative disorder affecting 1%\nof the population over the age of 60. The disease, which affected nearly 12\nmillion people worldwide in 2021, is characterized by the progressive loss of\ndopaminergic neurons. The LRRK2 gene is a major therapeutic target in\nParkinson’s disease. Activating mutations in the LRRK2 gene are associated\nwith hereditary forms of Parkinson’s disease. Along with alpha-synuclein,\nLRRK2 is one of the few targets considered to have the potential to modify the\ncourse of the disease. Current treatments are largely symptomatic and aim to\nincrease dopamine levels in the vicinity of the remaining dopaminergic\nneurons.\n\nAbout Oncodesign Precision Medicine (OPM)\n\nOncodesign Precision Medicine (OPM), founded in 2022, is a biopharmaceutical\ncompany specializing in precision medicine, dedicated to discovering\ntreatments for resistant and metastatic cancers.\n\nOPM currently has two kinase inhibitors in clinical phase:\n\n\n 1. OPM-101, intended for the treatment of chronic immuno-inflammatory digestive\ndiseases and immuno-oncology, has demonstrated a significant therapeutic\nmargin and absence of toxicity in its phase I healthy volunteers with the\nprotocol for the Phase 1b/2a oncology trial submitted at the end of March 2025\nand accepted in September 2025.\n\n 2. OPM-201, initially licensed to Servier and intended for the treatment of\nParkinson's disease, completed its phase I trial in healthy volunteers at the\nend of 2024, and was reintegrated into OPM's portfolio. In February 2026, OPM\nreceived funding from the Michael J. Fox Foundation for this program to\nprepare for the launch of a Phase 1b trial in 2027 involving people with\nearly-stage Parkinson’s disease, with a focus on those carrying an LRRK2\ngene mutation\n\nBoth molecules come from the Nanocyclix(®) technology platform, which enables\nthe design and selection of small, highly effective and selective macrocyclic\nkinase inhibitors. We now have 12,000 molecules in our library and will be\nusing AI to accelerate the discovery of drug candidates while reducing the\ncost of this phase.\n\nOPM's other two technology platforms are:\n\n\n * OncoSNIPER, for the selection of therapeutic targets using artificial\nintelligence,\n\n * PROMETHE(®) for the design and selection of radiolabeled biological molecules\nfor systemic radiotherapy.\n\nOPM, co-founded by Philippe Genne, Jan Hoflack and Karine Lignel, is based in\nDijon, at the heart of the university and hospital cluster, and employs 14\npeople.\n\nMore info at: oncodesign.com\n\nForward-looking statements\n\nThis document contains forward-looking statements and estimates with respect\nto the financial condition, results of operations, strategy, plans and future\nperformance of the Company and the market in which it operates. Some of these\nstatements, forecasts and estimates can be identified by the use of words such\nas, without limitation, \"believes\", \"anticipates\", \"expects\", \"projects\",\n\"plans\", \"seeks\", \"estimates\", \"may\", \"will\" and \"continue\" and other similar\nexpressions. They include all matters that are not historical facts. Such\nstatements, forecasts and estimates are based on various assumptions and\nassessments of known and unknown risks, uncertainties and other factors, which\nwere believed to be reasonable when they were made but which may not prove to\nbe correct. Actual events are difficult to predict and may depend on factors\nbeyond the Company's control. Consequently, the actual results, financial\nconditions, performance or achievements of the Company, or industry results,\nmay differ materially from future results, performance or achievements as\nexpressed or implied by such statements, forecasts and estimates. Given these\nuncertainties, no representation is made as to the accuracy or fairness of\nsuch forward-looking statements, forecasts and estimates. Furthermore, the\nforward-looking statements, forecasts and estimates speak only as of the date\nof publication of this document. The Company disclaims any obligation to\nupdate these forward-looking statements, forecasts or estimates to reflect any\nchange in the Company's expectations with regard thereto, or any change in\nevents, conditions or circumstances on which these statements, forecasts or\nestimates are based, except as required by French law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261007877096/en/\n(https://www.businesswire.com/news/home/20261007877096/en/)\n\nOPM \n\nKarine Lignel\n\nDeputy General Manager\n\nTel: +33 (0)310 451 820\n\ninvestisseurs@oncodesign.com (mailto:investisseurs@oncodesign.com)\n\nNewCap \n\nInvestor Relations\n\nMathilde Bohin / Alban Dufumier\n\nTel: +33 (0)1 44 71 94 95\n\noncodesign@newcap.eu (mailto:oncodesign@newcap.eu)\n\nNewCap \n\nMedia Relations\n\nArthur Rouillé\n\nTel: +33 (0)1 44 71 00 15\n\noncodesign@newcap.eu (mailto:oncodesign@newcap.eu)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-07T16:00:00.488349749Z","server_sent_at_ms":1791388800488},"received_at":"2026-10-07T16:00:00.539Z","source_url":"https://www.businesswire.com/news/home/20261007877096/en/"},"analysis":{"id":"151854","press_release_id":"163398","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Phase 1b in patients and IND submission not expected until 2027 — long timeline to clinical validation","micro-cap with 14 employees and no stated funding figures"],"eventType":"operations_update","narrative":"Oncodesign Precision Medicine (ALOPM) hit several milestones in its LARKIN program for OPM-201, its LRRK2 kinase inhibitor for Parkinson's disease, six months after launching the MJFF-funded program.\n\nMicronization of the API and the first technical batches of OPM-201 tablets were successfully completed, and the EMA's CHMP endorsed the long-term toxicology study plan on July 23, 2026.\n\nMJFF confirmed continued support by releasing an additional funding tranche on August 27, 2026, keeping the program on budget.\n\nOPM plans an IND submission in early 2027 with the objective of initiating a Phase 1b trial in Parkinson's patients in 2027.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"MJFF-backed Parkinson's asset stays on track toward 2027 Phase 1b — incremental de-risking, not a catalyst."},"keyFigures":{"drugName":"OPM-201","phaseOfTrial":"Phase 1b planned for 2027","customDimensions":{"employees":14,"molecule_library_size":12000,"ind_submission_planned":"early 2027","toxicology_study_start":"first half of 2027"}},"quotedText":"The LARKIN program remains on budget, and on August 27, 2026, OPM received a second payment from The Michael J. Fox Foundation following the achievement of the milestones defined under the program.","namedEntities":{"people":[{"name":"Philippe Genne","role":"co-founder, President and CEO"},{"name":"Jan Hoflack","role":"co-founder, Chief Scientific Officer"},{"name":"Karine Lignel","role":"co-founder, Deputy General Manager"},{"name":"Mathilde Bohin","role":"investor relations, NewCap"},{"name":"Alban Dufumier","role":"investor relations, NewCap"}],"products":["OPM-201","OPM-101","Nanocyclix","OncoSNIPER","PROMETHE"],"companies":[{"name":"Oncodesign Precision Medicine (OPM)","ticker":"ALOPM","relationship":"filer"},{"name":"The Michael J. Fox Foundation for Parkinson's Research (MJFF)","relationship":"funder"},{"name":"Servier","relationship":"former licensor"},{"name":"European Medicines Agency (EMA)","relationship":"regulator"},{"name":"U.S. Food and Drug Administration (FDA)","relationship":"regulator"},{"name":"NewCap","relationship":"IR/PR agency"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Progress update on the LARKIN program: API micronization and technical batch manufacturing completed, CHMP endorsed the long-term toxicology plan, and MJFF released an additional funding tranche. No clinical data or binary regulatory event; Phase 1b remains planned for 2027."},"tickerRelevance":{"others":[],"primary":"ALOPM"},"globalImportance":12,"audienceRelevance":8,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"development-milestone update, no data","sectorWeight":"biotech pre-revenue","householdBrandBoost":"MJFF name recognition minor"}},"event_type":"operations_update","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":2,"narrative":"Oncodesign Precision Medicine (ALOPM) hit several milestones in its LARKIN program for OPM-201, its LRRK2 kinase inhibitor for Parkinson's disease, six months after launching the MJFF-funded program.\n\nMicronization of the API and the first technical batches of OPM-201 tablets were successfully completed, and the EMA's CHMP endorsed the long-term toxicology study plan on July 23, 2026.\n\nMJFF confirmed continued support by releasing an additional funding tranche on August 27, 2026, keeping the program on budget.\n\nOPM plans an IND submission in early 2027 with the objective of initiating a Phase 1b trial in Parkinson's patients in 2027.","key_figures":{"drugName":"OPM-201","phaseOfTrial":"Phase 1b planned for 2027","customDimensions":{"employees":14,"molecule_library_size":12000,"ind_submission_planned":"early 2027","toxicology_study_start":"first half of 2027"}},"named_entities":{"people":[{"name":"Philippe Genne","role":"co-founder, President and CEO"},{"name":"Jan Hoflack","role":"co-founder, Chief Scientific Officer"},{"name":"Karine Lignel","role":"co-founder, Deputy General Manager"},{"name":"Mathilde Bohin","role":"investor relations, NewCap"},{"name":"Alban Dufumier","role":"investor relations, NewCap"}],"products":["OPM-201","OPM-101","Nanocyclix","OncoSNIPER","PROMETHE"],"companies":[{"name":"Oncodesign Precision Medicine (OPM)","ticker":"ALOPM","relationship":"filer"},{"name":"The Michael J. Fox Foundation for Parkinson's Research (MJFF)","relationship":"funder"},{"name":"Servier","relationship":"former licensor"},{"name":"European Medicines Agency (EMA)","relationship":"regulator"},{"name":"U.S. Food and Drug Administration (FDA)","relationship":"regulator"},{"name":"NewCap","relationship":"IR/PR agency"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-07T16:00:07.719Z","global_importance":12,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"development-milestone update, no data","sectorWeight":"biotech pre-revenue","householdBrandBoost":"MJFF name recognition minor"}},"durationMs":7160,"modelName":"glm-5.3-flashx"}}